CEBP epigenetic dysregulation as a drug target for the treatment of hematologic and gynecologic malignancies.

CEBP epigenetic dysregulation as a drug target for the treatment of hematologic and gynecologic malignancies. Curr Drug Targets. 2016 Dec 28; Authors: Sun C, Duan P, Luan C Abstract The CCAAT/enhancer binding proteins (C/EBPs) form a family of transcription factors regulating many genes' expression in a variety of cells/tissues/organs at different developmental stages. With their capability of binding to a loosely defined consensus DNA sequence and through extensive protein-protein interactions, C/EBPs modulate diverse functions including cell differentiation, metabolism, and immune response, under both physiological and pathological conditions such as the establishment of hematological lineages, the maintenance of normal reproductive function, and the development of malignant disease. Accumulated data have shown that C/EBPs themselves are subject to dynamic regulation of different signaling pathways at transcription and posttranscriptional levels, which adds another dimension to the complexity of C/EBP activity. This review concentrates on the role(s) and epigenetic alterations of C/EBP genes in hematologic malignancies and gynecologic organs and disorders. Germ line and somatic mutations along with their pathological implications are provided as background information. New research findings on molecular pathways involved in C/EBP function and regulation are reviewed and analyzed. The potential therapeutic values of these findings a...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research